PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

Columnist Colleen Steele says that glimmers are like an antidote to some of the events that spark her caregiving anxiety.

Following the first sale of Yutrepia to treat certain types of PH, Liquidia has received $50 million under its financing ...

A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with PAH has completed enrollment.

Columnist Anna Jeter is delighted to find themes that are relevant to her life in the fictional narratives of writers and ...

Adding Winrevair treatment significantly reduced the risk of clinical worsening in people with a recent PAH diagnosis, per a ...

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

Streamlining collaboration with FDA “We’re excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA — from initiating our pivotal clinical study to ...

According to Cereno, the upcoming Phase 2b trial will test CS1 against a placebo in a larger group of PAH patients, and evaluate the therapy’s effects on vascular remodeling and right heart function.

Yutrepia’s approval marks progress toward a better treatment landscape for people with PAH and PH-ILD — both forms of pulmonary hypertension marked by elevated pressure in the blood vessels of the ...